Levetown & Jenkins, LLP is conducting an investigation into alleged breaches of fiduciary duties and violations of state law by Clarient, Inc. (“Clarient”) (NASDAQ: CLRT) and its Board of Directors in conjunction with the proposed buyout and acquisition of Clarient by GE Healthcare, a unit of General Electric Company (NYSE: GE). Under the terms of a definitive merger agreement announced on October 22, 2010, Clarient shareholders will receive a tender offer for all outstanding common and preferred shares of Clarient at $5.00 per common share and $20.00 per preferred share, payable in cash. The transaction is valued at approximately $580 million, net of cash and investments as of June 30, 2010. The firm’s investigation concerns whether the proposed acquisition properly values Clarient. Specifically, the investigation seeks to determine whether the Clarient Board of Directors engaged in a fair process to obtain adequate consideration for all of the company's shareholders, whether the transaction undervalues the company to the detriment of its shareholders and, if so, the extent to which the company is undervalued in the proposed transaction. Levetown & Jenkins, LLP is a national law firm comprised of former federal and state prosecutors with extensive experience in the investigation and prosecution of shareholder fraud. The firm specializes in the representation of investors in shareholder and securities fraud class actions. If you currently own shares of Clarient and wish to obtain additional information about your rights as a shareholder, please contact Michael T. Harrison, Esq. at (713) 392-7465 or email@example.com. For more information about the firm, please visit www.levjen.com. Attorney Advertising. (C) 2010 Levetown & Jenkins, LLP. The law firm responsible for this advertisement is Levetown & Jenkins, LLP ( www.levjen.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.